Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | |||
| Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
| Signifor | Pasireotide diaspartate | Cushing’s disease | Do not list | Complete | ||
| Siliq | brodalumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Silkis | Calcitriol | Psoriasis, mild to moderate plaque | Do not list | Complete | ||
| Simbrinza | Brinzolamide / brimonidine | Glaucoma and ocular hypertension | List | Complete | ||
| Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
| Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | ||
| Simponi | Golimumab | Ankylosing spondylitis | List in a similar manner | Complete |
Last Updated : April 27, 2024